Aldeyra Therapeutics (ALDX) Share-based Compensation (2013 - 2026)
Aldeyra Therapeutics' (ALDX) quarterly Share-based Compensation came in at -$987554.0 in Q1 2026, down 144.4% YoY from $2.2 million in Q1 2025, and down 117.05% on a QoQ basis from $5.8 million in Q4 2025.
Aldeyra Therapeutics (ALDX) Share-based Compensation (2013 - 2026) Analysis & Trends
Aldeyra Therapeutics (ALDX) has 14 years of Share-based Compensation data on file, last reported at -$987554.0 in Q1 2026.
- Quarterly Share-based Compensation fell 144.4% year-over-year to -$987554.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.2 million (down 16.47% YoY) and the FY2025 annual result came in at $6.1 million, down 23.6% from the prior year.
- Share-based Compensation fell to -$987554.0 in Q1 2026, from $5.8 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $5.8 million in Q4 2025 to a low of -$6.0 million in Q4 2023.
- A 5-year average of $1.5 million and a median of $1.6 million in 2023 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2023 — Share-based Compensation tumbled 313.38% — and 2025, when it jumped 358.42%.
- Tracing ALDX's Share-based Compensation over 5 years: stood at $2.8 million in 2022, then plunged by 313.38% to -$6.0 million in 2023, then surged by 120.99% to $1.3 million in 2024, then jumped by 358.42% to $5.8 million in 2025, then slumped by 117.05% to -$987554.0 in 2026.
- The last three Share-based Compensation figures came in at -$987554.0 (Q1 2026), $5.8 million (Q4 2025), and $900000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Aldeyra Therapeutics | 91.08 Mn | 91.08 Mn | - | 1.64 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.64 Mn |
| Jun 30, 2026 | 1.64 Mn |
| Mar 31, 2026 | -987,554.00 |
| Mar 31, 2026 | -987,554.00 |
| Dec 31, 2025 | 5.79 Mn |
| Dec 31, 2025 | 5.79 Mn |
| Sep 30, 2025 | 900,000.00 |
| Sep 30, 2025 | 900,000.00 |
| Jun 30, 2025 | 196,564.00 |
| Jun 30, 2025 | 196,564.00 |
| Mar 31, 2025 | 2.22 Mn |
| Mar 31, 2025 | 2.22 Mn |
| Dec 31, 2024 | 1.26 Mn |
| Dec 31, 2024 | 1.26 Mn |
| Sep 30, 2024 | 3.23 Mn |
| Sep 30, 2024 | 3.23 Mn |
| Jun 30, 2024 | 1.94 Mn |
| Jun 30, 2024 | 1.94 Mn |
| Mar 31, 2024 | 1.55 Mn |
| Mar 31, 2024 | 1.55 Mn |